Drug Type Monoclonal antibody |
Synonyms SM17单克隆抗体, SM17 |
Target |
Action modulators, inhibitors |
Mechanism IL-25 modulators(interleukin 25 modulators), IL17RB inhibitors(Interleukin-17 receptor B inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Dermatitis, Atopic | Phase 1 | China | 21 Nov 2023 | |
| Moderate Atopic Dermatitis | Phase 1 | China | 21 Nov 2023 | |
| Severe Atopic Dermatitis | Phase 1 | China | 21 Nov 2023 | |
| Asthma | Phase 1 | United States | 14 Jun 2022 | |
| Idiopathic Pulmonary Fibrosis | Preclinical | China | 10 Jan 2019 | |
| Idiopathic Pulmonary Fibrosis | Preclinical | United Kingdom | 10 Jan 2019 |
Phase 1 | - | - | bzshhyrhmf(ufjvrgrlmm) = jqpaeijdnx hnsomdhauw (gqukwifwmp ) View more | Positive | 14 Oct 2025 |






